BIO feed
Trials, approvals, platforms and the business of biology.
31 stories · 6 editions
Biomedical coverage describes AI in lab workflows, clinical trials and radiology.
TL;DR
Two reports raise different questions about GLP-1 medicines and weight-related outcomes.
Public-health reporting on a U.S. outbreak sits alongside research coverage on emerging infectious diseases.
A claims-based study reported nutritional deficiency diagnoses among pediatric GLP-1 receptor agonist users.
A UK Biobank analysis linked measured sleep stages with later disease incidence across a broad set of outcomes.
An FDA advisory panel backed Grail’s multi-cancer blood test on benefit-risk questions; the agency has not made its approval decision.
The panel vote moves multi-cancer early detection toward an FDA decision that also gates insurance coverage.
New papers tested clinical LLMs on stability, bias and reproducibility rather than headline accuracy.
Deployment research focused on how AI changes clinical roles and how its outcomes should be measured.
Registry updates showed new and established sponsors across RAS inhibition, prostate, uterine and brain cancers.
Investors are returning to bone-loss therapies as evidence for common supplements looks thin.
New work argues the human and workflow context around a clinical AI matters more than how it explains itself.
Machine-learning prediction and monitoring studies clustered around acute and critical care.
Cancer news spanned an FDA advisory vote, a new approval and registered combination trials.
AI-assisted modelling and triage tools met a resurgent filovirus and a deep-time lesson on plague.
A preprint used genomic language modelling to design biosynthetic pathways while clinical work pushed new biomarkers.
Brain science ranged from a two-organ hypothesis to implants, long-COVID imaging and dementia prediction.
Novo's Medicare pricing terms and fresh evidence on stopping GLP-1 drugs both landed the same day.
A capital-markets-day reset for Novo landed alongside a meta-regression on GLP-1 stroke and cognitive outcomes.
A Galleri advisory-committee vote, a Lilly approval and a radiopharma merger set the day's regulatory tone.
Clinical AI moved from benchmarks toward deployment — and one paper flagged a gap between algorithmic scores and decisions.
Resilience, not only pathology, is emerging as the predictive variable in dementia research.
Editing and RNA therapies advanced, and researchers solved a 50-year mystery by finding a new human blood group.
An effectiveness study and a trust-and-information story show the two halves of the vaccination problem.
Flu antigenic drift, repeated SARS-CoV-2 introductions and a surging Ebola relative point to the value of early warning.
New disease models, an Amish cohort study and an analysis of repurposing candidates all point at the same target from different directions.
Papers on AI in trials, patient-facing generative AI and a geriatrician's commentary converge on evaluation as the binding constraint.
An approval for an ultra-rare disease arrived alongside preclinical gene-therapy work and a review of CRISPR-based biosensors.
A first-in-human neuromodulation trial overlaps with basic work on how amygdala neurons join valence-related ensembles and with a developmental study of anxiety.
Observational diet research and two cardiovascular studies on gut microbiota and on religiosity add to the evidence base without settling causation.
New and updated registry entries spanned AI cardiac imaging, a supplement trial, metabolic and oncology studies, and an AI review of diabetes self-management.